beForm Nutrition Announces Sponsorship of the Ilkley Half Marathon 2025
Ben Bunting
LEEDS, United Kingdom, March 17, 2025 (GLOBE NEWSWIRE) -- beForm Nutrition, a leading dietary supplement company dedicated to supporting endurance athletes, is proud to announce its official sponsorship of the Ilkley Half Marathon 2025, taking place on 13th July 2025.
Founded by Ben Bunting, a qualified sports nutritionist and Army Physical Training Instructor, beForm Nutrition is committed to helping runners optimise their performance, recovery, and overall health.
The Ilkley Half Marathon is renowned for its scenic and challenging course, attracting participants from all over the UK. This year, the event introduces a brand-new 5k race, broadening its appeal to more runners of all abilities.
As part of its sponsorship, beForm Nutrition will have a strong presence in the Athletes' Village, where runners will have the opportunity to sample free, high-quality supplements specially formulated to enhance endurance, aid recovery, and prevent nutritional deficiencies common in long-distance running.
In addition to providing expert nutritional support to participants, beForm Nutrition's founder, Ben, will personally take on the challenge of the Ilkley Half Marathon, demonstrating his commitment to both the running community and the effectiveness of the products he has developed.
'We are thrilled to be sponsoring the Ilkley Half Marathon this year,' said Ben Bunting, Founder of beForm Nutrition.
'As a passionate advocate for endurance sports, I understand the importance of proper nutrition in achieving peak performance. This event is a fantastic opportunity for us to engage with the running community, help raise important funds for local charities, provide valuable insights, and offer products that truly make a difference."
A key aspect of the Ilkley Half Marathon is its commitment to charitable giving, with proceeds from the race going to various charities. beForm Nutrition is proud to support an event that not only challenges runners but also gives back to important causes within the local area.
beForm Nutrition invites all runners and spectators to visit their stand in the Athletes' Village to learn more about their innovative products, get expert advice, and experience first-hand the benefits of their supplements.
For more information about beForm Nutrition and its commitment to supporting endurance athletes, visit www.beformnutrition.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c0741b34-1ae4-489e-9c92-d49d6abf7076
CONTACT: CONTACT Benjamin Bunting COMPANY beForm Nutrition EMAIL: hello@beformnutrition.com WEB: https://beformnutrition.com/Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
SeekOut Appoints Veteran B2B Executive Bala Vishwanath as Chief Marketing Officer to Lead Talent Acquisition's Agentic AI Revolution
Enterprise Marketing Leader Joins to Accelerate Industry Transformation as Companies Race from AI-Powered to AI-Autonomous Recruiting Bala Vishwanath SEATTLE, June 05, 2025 (GLOBE NEWSWIRE) -- SeekOut, the Agentic AI talent acquisition platform, today announced Bala Vishwanath as Chief Marketing Officer, positioning the company to lead recruiting's most fundamental transformation since the dawn of the internet. This strategic appointment comes as enterprises have an unprecedented opportunity to embrace Agentic AI and gain significant competitive advantages in securing top talent. The talent acquisition industry stands at a critical inflection point. While many organizations celebrate basic AI-powered tools that assist recruiters, a seismic shift to autonomous AI agents is already underway. These agents work continuously, sourcing across platforms, conducting deep research and managing personalized campaigns with superhuman scale and precision. Organizations that embrace this evolution early will gain tremendous competitive advantages in securing exceptional talent. "We're witnessing the emergence of Vertical AI with specialized autonomous agents built for specific functions," said Anoop Gupta, co-founder and CEO of SeekOut. "Just as AI transformed finance and healthcare, it's now redefining talent acquisition. Bala understands how to evangelize category-defining transformations. He'll ensure every enterprise leader grasps a simple truth: Agentic AI isn't coming. It's here, and it's creating incredible opportunities for forward-thinking organizations." SeekOut bridges the transformation gap with two revolutionary approaches. SeekOut Recruit represents the "you do it" solution, empowering internal teams with AI superpowers, including semantic search across one billion profiles and intelligent automation. For organizations ready to leap forward, SeekOut Spot delivers the "we do it" experience through true Agentic AI, where autonomous agents work alongside expert advisors to deliver qualified, interested candidates in 3 to 14 days, versus the industry's 60- to 80-day standard. "Every filled position with exceptional talent becomes a competitive advantage for your organization," said Bala Vishwanath. "SeekOut Spot doesn't just accelerate hiring. It fundamentally breaks the speed-quality paradox that has plagued recruiting forever. When AI agents evaluate thousands of candidates in parallel while human experts ensure nuance and fit, you don't get incremental improvement. You get transformation. My mission is simple: help every talent leader understand the incredible opportunities this transformation creates and how they can lead the way in their industry." With over 25 years leading B2B marketing transformations, including establishing CoreStack as the definitive enterprise cloud governance leader, Vishwanath will spearhead SeekOut's market expansion as enterprises worldwide embrace Agentic AI. About SeekOut SeekOut is the Agentic AI talent acquisition platform transforming how enterprises discover and hire exceptional talent. The company's dual approach includes SeekOut Recruit, the "you do it" AI-powered platform trusted by over 1,000 enterprises, and SeekOut Spot, the "we do it" Agentic AI service where autonomous agents and expert advisors deliver complete hiring outcomes. Founded in 2018, SeekOut has raised $189 million from Tiger Global, Madrona and Mayfield, achieving a $1.2 billion valuation. Learn more at A photo accompanying this announcement is available at CONTACT: Media Contact: Kate Achille The Devon Group for SeekOut kate@
Yahoo
30 minutes ago
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
Yahoo
31 minutes ago
- Yahoo
Regulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - Trends, Opportunities, and Forecasts 2020-2030
Regulatory Affairs Outsourcing Market Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Regulatory Affairs Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Regulatory Affairs Outsourcing Market was valued at USD 6.84 Billion in 2024, and is expected to reach USD 11.94 Billion by 2030, rising at a CAGR of 9.73% Market expansion is primarily driven by increased R&D efforts and a rising number of clinical trial applications and product registrations. Additionally, regulatory measures aimed at controlling drug costs are generating economic pressures that encourage life sciences companies to outsource regulatory functions. The COVID-19 pandemic further accelerated this trend, as the urgent development of vaccines underscored the importance of streamlined regulatory processes. As globalization continues, companies entering international markets face a complex web of regulatory standards, prompting greater reliance on external expertise to navigate compliance efficiently. This demand is especially strong in emerging markets where operational costs are lower and regulatory environments are increasingly attractive for Market Drivers Globalization of Biopharmaceutical and Medical Device CompaniesThe expansion of biopharmaceutical and medical device companies into international markets is a major driver behind the growth of regulatory affairs outsourcing. Each new market introduces unique compliance requirements, demanding specialized regulatory knowledge. Outsourcing helps companies manage these challenges efficiently and cost-effectively. Emerging regions such as Asia Pacific, Latin America, and the Middle East & Africa are particularly appealing due to lower development costs, skilled labor availability, and favorable regulatory climates. For instance, infrastructure investments like B. Braun's five new facilities in Malaysia and Flex Ltd.'s site in India reflect the trend of companies expanding regionally while leveraging outsourced regulatory expertise to ensure Market Challenges Data Security and Privacy ConcernsSecurity and privacy of sensitive regulatory information are critical challenges in this market. As outsourcing increases, so does the risk of data breaches and cyberattacks. The growing use of digital platforms - such as electronic Common Technical Document (eCTD) submissions and digital IND safety reporting - amplifies vulnerabilities. Additionally, mergers and acquisitions within the healthcare sector can expose organizations to greater cybersecurity threats due to the volume and sensitivity of exchanged data, posing a significant risk to business continuity and regulatory Market Trends Technological Advancements in Regulatory ProcessesTechnological progress is reshaping regulatory affairs outsourcing, introducing tools that enhance transparency, speed, and collaboration. Regulatory Information Management Systems (RIMS) are streamlining submission tracking and compliance monitoring. Cloud-based platforms enable real-time interaction between clients and service providers, improving operational efficiency. Furthermore, artificial intelligence (AI) and machine learning are being used to automate administrative tasks like data entry and document processing, allowing regulatory professionals to focus on strategic functions. These technologies are optimizing regulatory workflows, making it easier for companies to meet global compliance standards swiftly and accurately. Key Attributes: Report Attribute Details No. of Pages 180 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $6.84 Billion Forecasted Market Value (USD) by 2030 $11.94 Billion Compound Annual Growth Rate 9.7% Regions Covered Global Report Scope: Competitive LandscapeCompany Profiles: Detailed analysis of the major companies present in the Global Regulatory Affairs Outsourcing Market. Accell Clinical Research, LLC. Genpact Ltd. CRITERIUM, INC. Promedica International. WuXi AppTec Co Ltd. Medpace Inc. Charles River Laboratories Inc. ICON plc. Covance, Inc. Parexel International Corporation. Regulatory Affairs Outsourcing Market, By Service: Regulatory Consulting Legal Representation Regulatory Writing & Publishing Product registration & clinical trial applications Regulatory Submissions Regulatory Operations Other services Regulatory Affairs Outsourcing Market, By Category: Pharmaceutical Medical Device Regulatory Affairs Outsourcing Market, By Company Size: Small Companies Medium Companies Large Companies Regulatory Affairs Outsourcing Market, By Indication: Oncology Neurology Cardiology Immunology Other Indications Regulatory Affairs Outsourcing Market, By Product Stage: Preclinical Clinical Premarket Approval Regulatory Affairs Outsourcing Market, By End Use: Medical Device Companies Pharmaceutical Companies Biotechnology Companies Regulatory Affairs Outsourcing Market, By Region: North America United States Canada Mexico Europe France Germany United Kingdom Italy Spain Asia Pacific China India Japan South Korea Australia South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Regulatory Affairs Outsourcing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
